Evidence map›Paper›PMID 41735359›Full record

ArticleScientific reports2026

Cancer-Associated fibroblasts regulate the development of cholangiocarcinoma through IL-6/STAT3/AKR1C3 signaling axis.

Tian-Cong Huang, Wen-du Feng, Guo-Xu Fang, Qing-Hua Zhang, Guang-Ya Wei, Cheng-Zong Li, Jian-Min Wang, Jing-Feng Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tian-Cong Huang *Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, China.
Wen-du Feng *Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, China.
Guo-Xu Fang *Department of Hepatopancreatobiliary Surgery, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China.
Qing-Hua ZhangClinical Oncology School, Fujian Medical University, Fuzhou, 350108, China.
Guang-Ya WeiClinical Oncology School, Fujian Medical University, Fuzhou, 350108, China.
Cheng-Zong LiDepartment of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, China.
Jian-Min WangInnovation center for cancer research, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, 350108, China. drjingfeng@fjmu.edu.cn.
Jing-Feng LiuThe Big Data Institute of Southeast Hepatobiliary Health Information, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, 350025, China. wangjm8605@163.com.

Funding

the Natural Science Foundation of Fujian Province 2022J01776
6 · The paper itself

Abstract

Cancer-associated fibroblasts (CAFs) are the dominant component of the tumor microenvironment (TME), which contributes to tumor progression. Aldo-keto reductase 1 family member C3 (AKR1C3) has been correlated with the development of various kinds of cancers. Nevertheless, the effect and mechanism of CAFs on AKR1C3 in cholangiocarcinoma (CCA) remain unelucidated. Q-PCR assay and IHC were conducted to detect the expression of AKR1C3 in CCA tissues. Subsequently, CCK8 assay, colony formation, crystal violet assay, apoptosis assay, glucose uptake, and lactate production assay were performed to investigate the effect of AKR1C3 on the biological function of CCA cells. The regulatory effect of CAFs on AKR1C3 was examined in CCA cells cultured with a CAF-conditioned medium. Finally, western blot, co-immunoprecipitation, and ubiquitination degradation kits were used to explore the potential molecular mechanism. AKR1C3 was overexpressed in CCA tissues compared to normal tissues. Patients with a high staining intensity score of AKR1C3 exhibited a poor overall survival time. AKR1C3 was found to enhance the proliferation, colony formation, drug resistance, and aerobic glycolysis of CCA cells. Moreover, CAFs modulate the overexpression of AKR1C3 in the onset and progression of CCA through the IL-6/STAT3 signaling pathway. This regulation occurs via the IL-6/STAT3/AKR1C3 signaling axis, indicating that targeting AKR1C3 could serve as a potential therapeutic strategy for patients with CCA.

Indexed as

Aldo-Keto Reductase Family 1 Member C3Bile Duct NeoplasmsCancer-Associated FibroblastsCholangiocarcinomaInterleukin-6Signal TransductionSTAT3 Transcription FactorApoptosisCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleTumor MicroenvironmentAKR1C3 protein, humanAldo-Keto Reductase Family 1 Member C3IL6 protein, humanInterleukin-6STAT3 protein, humanSTAT3 Transcription FactorAKR1C3Cancer-associated fibroblastsCholangiocarcinomaIL-6/STAT3 signalingOncogene.

Identifiers

PMID41735359
PMCPMC13031540

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.